Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART22 in Pediatric and Young Adult Relapsed/Refractory B-cell ALL
NCT02650414Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jan 2016
- Primary completion
- Dec 2037
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CART22 in acute lymphoblastic leukemia (ALL) (4 arms), sponsored by University of Pennsylvania. Primary endpoint: Frequency and severity of adverse events at 15 years. Started Jan 2016; status: active, not recruiting.
02
Drugs
CART22
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02650414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02650414.